Biognosys Expands Co-Marketing Agreement with Global Life Science Leader to Advance Proteomics
14.12.2021 18:00:00 EET | Business Wire | Press release
Biognosys, a leading developer and provider of next-generation proteomics technology and solutions, and Thermo Fisher Scientific, the world leader in serving science with innovative technologies, purchasing convenience and pharmaceutical services, announced today that they have extended a co-marketing agreement to provide life science researchers with comprehensive mass spectrometry solutions to gain deep proteomics insights at a large scale.
The agreement leverages the two companies’ complementary capabilities in mass spectrometry-based proteomics. Biognosys deploys Thermo Fisher Scientific instruments in its state-of-the-art facility for contract research services, while Thermo Fisher Scientific co-markets Biognosys software and kits with its Thermo Scientific™ instruments and workflows.
Biognosys’ Biomarker Discovery services for pharmaceuticals and diagnostics development integrate Thermo Scientific Orbitrap™ and FAIMS Pro™ instruments with Biognosys’ proprietary, patented Hyper Reaction Monitoring (HRM™) technology and Spectronaut™ Data Independent Acquisition (DIA) analysis software to offer unprecedented depth, quantitative precision, and throughput for unbiased discovery. This new and improved solution searches the complete proteome to quantify up to 3,000 of the most relevant proteins in biofluids and more than 10,000 proteins in tissue biopsies.
Andreas Huhmer, PhD, Senior Director Life Sciences Research OMICS Marketing at Thermo Fisher Scientific: “Biognosys’ Biomarker Discovery solutions maximize all innovative features of the Thermo Scientific Orbitrap mass spectrometers to analyze the proteome with industry-leading depth. Their unbiased discovery approach, coupled with their state-of-the-art data analysis capabilities, unlocks possibilities for transformative biomarker discovery.”
Through the companies’ extended co-marketing agreement, laboratories with in-house proteomics facilities have access to efficient, accurate, and scalable mass spectrometry-based proteomics workflows combining Thermo Scientific mass spectrometry instruments with Biognosys’ proteomics data analysis software and kits.
Lukas Reiter, PhD, Chief Technology Officer of Biognosys: “Our agreement with Thermo Fisher Scientific has helped to greatly advance Biognosys’ mission to give researchers a look at every angle of the proteome to unlock discoveries and transform clinical research. Our suite of software and kits uniquely complements Thermo Scientific mass spectrometry instruments and workflows to enable researchers to obtain the best possible data and insights in any proteomics application.”
Biognosys’ leading DIA software solution, Spectronaut, is compatible with Thermo Scientific Orbitrap Exploris™ 480 and Thermo Scientific™ Q Exactive™ instruments.
Biognosys’ SpectroDive™ software for automated mass spectrometry method set-up, signal processing, and analysis of targeted proteomics experiments supports the SureQuant IS-PRM targeted acquisition workflow.
The PQ500™ Reference Peptide Kit from Biognosys can quantify more than 500 proteins in human plasma/serum samples as part of the SureQuant IS-PRM workflow with the Orbitrap Exploris™ 480 mass spectrometer, delivering sensitive and accurate quantitation to drive scientific progress or clinical decision making.
Learn more about the insights that can be uncovered through the Biognosys and Thermo Fisher Scientific partnership from Lukas Reiter’s presentation, “Recent Progress in Blood Proteomics”, during the Thermo Fisher Scientific dinner workshop at ASMS 2021.
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005070/en/
Contact information
Media Contact
Yves Serroen
Head of Marketing
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom